A REVIEW ON TREATMENT OF CANCER BY NOVEL DRUG DELIVERY SYSTEM

Bhanupriya Taram, Deepial Priya Bennett, Gyanesh Kumar Sahu

Abstract


Cancer is one of the most fatal diseases in all over the world. Due to which, many countries trying to implement various curable treatments for decades. Since last 20th century new improved methods and treatments were developed like chemotherapy and radiation therapy, which gives an effective result along with surgery. Medicines are also imparted with newly modern changes called as novel drugs and novel drug delivery system (NDDS). Novel drug delivery system (NDDS) is a new approach to gives improved form of medications with its therapeutic effects. This delivery system ease the overall treatment by providing targeted action, controlled release of active pharmaceutical ingredients with maintaining systemic circulations and enhance drugs therapeutic effects with dosage. It includes Microsphere, Nanoparticle, Dendrimer, Liposome, Niosome and Ethosome type of delivery system.

 

Keywords: -

Cancer, Novel drug delivery system (NDDS), Nanoparticle, Microsphere, Liposome, Niosome.


Full Text:

PDF

References


Zubair, H., & Ahmad, A Cancer Metastasis. Introduction to Cancer Metastasis, (2017), 3–12.

Vogelstein, B., Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med. (2004), 10, 789–799.

M. Mareel, A. Leroy, Clinical, cellular and molecular aspects of cancer invasion, Physiol. Rev. 83 (2003), 337-376.

Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997); 3:730–7.

J. Wesche, K. Haglund, E.M. Haugsten, Fibroblast growth factors and their receptors in cancer, Biochem. J. 437 (2011), 199-213.

M.M. Gottesman, T. Fojo, S.E. Bates, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat. Rev. Cancer, 2 (2002), 48-58.

Jorgensen, T.L. et al. Comorbidity and polypharmacy in elderly cancer patients: the significance on treatment outcome and tolerance. J. Geriatr. Oncol. (2010) 1, 87–102.

Kelloff GJ, Sigman CC, Greenwald P. Cancer chemoprevention: progress and promise. Eur J Cancer. Dec (1999); 35(13):1755-1762.

Wu X, Patterson S, Hawk E. Chemoprevention--history and general principles. Best Pract Res Clin Gastroenterol. Aug (2011); 25(4-5):445-459.

Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. (2015); 16(15):e534–e542.

Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. (2015) ;11(9):504–514.

International Commission on Radiation Units and Measurements (ICRU), Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). ICRU Report 83 (Bethesda, MD: ICRU); (2010).

Lagendijk JJ et al. In room magnetic resonance imaging guided radiotherapy (MRIgRT). Med Phys (2005); 32:2067.

Anon, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. (1997), Lancet 350 (9084), 1047–1059.

Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature (2001); 414:105–11.

Pierce B, Verney EL, Dixon FJ. The biology of testicular cancer: I. Behavior after transplantation. Cancer Rea (1957): 17:134-8.

Waddington CH. Genetic assimilation of the bithorax phenotype. Evolution (1956); 10:1–13.

Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern incolorectal cancer is strongly influenced by histological subtype. Ann Oncol Off J EurSoc Med Oncol (2014); 25:651e7.

Gujjar S and Khatri S. A review on basic concept of drug targeting and drug carrier system. International Journal of Advances in Pharmacy, Biology and Chemistry (2013), 2(1):130–136.

D.M. Molina, R. Jafari, M. Ignatushchenko, T. Seki, E. A. Larsson, C. Dan, L.Sreekumar, Y. Cao, P. Nordlund, Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay, Science 341 (2013), 84-87.

Agnihotri J, Saraf S, and Khale A. Targeting: New potential carriers for targeted drug delivery system. International Journal of Pharmaceutical Sciences Review and Research (2011),8(2): 117–123.

Heller J. Polymers for controlled parenteral delivery of peptides and proteins. Advanced Drug Delivery Reviews (1993),10(2): 163–204.

Huang X and Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. Journal of Controlled Release (2001), 73(2–3): 121–136.

S. Harsha, R. Chandramouli, S. Rani S, Ofloxacin targeting to lungs by way of microspheres, Int. J. Pharm. 380 (2009) 127-132.

U. Edlund, A.C. Albertsson, Degradable polymer microspheres for controlled drug delivery, Adv. Polymer Sci.157 (2002), 67-112.

Arrieta O, Medina LA, Estrada-Lobato E, Hernandez-Pedro N, Villanueva-Rodriguez G, Martinez-Barrera L, et al. First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer (2012), ;106:1027e32.

Reck, M., Heigener, D.F., Mok, T., Soria, J.-C., Rabe, K.F. Management of non-small-cell lung cancer: recent developments. Lancet (2013), 382, 709–719.

Miyazaki, S.; Hashiguchi, N.; Hou, W. M.; Yokouchi, C.; Takada, M. Chem. Pharm. Bull. 34, (1986), 3384-3393.

Denison CR, inventor; MAGNAVOX AUSTRALIA Pty Ltd, assignee. Magnetic unit with magnetically positioned pole piece for loudspeakers. United States patent US 2,604,551. (1952), Jul 22.

Stroumpoulis D, Kayda EJ, inventors; Allergan Inc, assignee. Dual Cartridge Mixer Syringe. United States patent application US 12/909,216. (2012), Apr 26.

Ma G, Su Z, Wei W, Wang L, Wei Q, inventors; Institute of Process Engr Chinese Academy od Science, assignee. Method of imaging with fluorescent microspheres. United States patent US 8,460,638. (2013), Jun 11.

Jain S, Jain V, and Mahajan SC. Lipid based vesicular drug delivery systems. Advances in Pharmaceutics (2014) : 574673.

McBain SC, Yiu HH, and Dobson J .Magnetic nanoparticles for gene and drug delivery. International Journal of Nanomedicine 3(2): (2008), 169–180.

S. Touhey, R. O’Connor, S. Plunkett, A. Maguire, M. Clynes, Structure–activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition: identification of novel chemotherapeutic drug resistance modulators, Eur. J. Cancer 38 (2002) 1661–1670.

G.S. Kwon, Polymeric micelles for delivery of poorly water-soluble compounds,Crit. Rev. Ther. Drug Carrier Syst. 20 (2003) 357–403.

Farr I, Lambright TM, inventors; Hewlett Packard Development Co LP, assignee. Core-shell solid freeform fabrication. United States patent US 7,829,000. (2010), Nov 9.

Zale SE, Ali MM, inventors; Bind Therapeutics Inc, assignee. Cancer cell targeting using nanoparticles. United States patent US 8,603,499. (2013), Dec 10.

Lian T and Ho RJ. Trends and developments in liposome drug delivery systems. Journal of Pharmaceutical Sciences (2001), 90(6): 667–680.

Shigehiro T, Kasai T, Murakami M, et al. Efficient Drug Delivery of Paclitaxel Glycoside: A Novel Solubility Gradient Encapsulation into Liposomes Coupled with Immunoliposomes Preparation. PLoS One. (2014); 9(9).

Y. Kumada, K. Tomioka, S. Katoh, Characteristics of liposome immunosorbent assay (LISA) using liposomes encapsulating coenzyme β-NAD+, J. Chem. Eng. Japan. 34 (2001) 943–947.

Y. Kumada, M. Maehara, K. Tomioka, S. Katoh, Liposome immunoblotting assay using a substrate-forming precipitate inside immunoliposomes, Biotechnol. Bioeng. 80 (2002),414–418.

Y.S. Krishnaiah, V. Satyanarayana, B. Dinesh Kumar, R.S. Karthikeyan, In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil, Eur. J. Pharm. Sci. 16 (2002) 185–192.

V.R. Sinha, B.R. Mittal, K.K. Bhutani, R. Kumria, Colonic drug delivery of 5-fluorouracil: an in vitro evaluation, Int. J. Pharm. 269 (2004), 101–108.

Sharma, A., Sharma, U. S., Straubinger, R. M. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Letters (1996), 107, 265-272.

Wang AJ, Wang PL, Lu SJ, inventors; Industrial Technology Research Institute, assignee. Long circulating liposome. United States patent application US 11/023,525. (2005), Jun 30.

Marnett LJ, Honn KV, Johnson CR, Chen YF, Shimoji KI, inventors; Wayne State University, assignee. Cyclic hydroxamic acids. United States patent US 5,234,933. (1993), Aug 10.

Uchegbu, I.J., Vyas, S.P. Non-ionic surfactant based vesicles (niosomes) in drug delivery. International Journal of Pharmaceutics (1998),172, 33–70.

Manosroi, A., Wongtrakul, P., Manosroi, J., Sakai, H., Sugawara, F., Yuasa, M., Abe, M . Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids and Surfaces B: Biointerfaces (2003), 30, 129–138.

Buckton G. Interfacial phenomena in drug delivery and targeting. Switzerland:Harwood Academic Publishers; (1995), p. 154-5.

M.P. Cole, C.T. Jones, I.D. Todd, A new anti-oestrogenic agent in late breast cancer.An early clinical appraisal of ICI46474, Br. J. Cancer 25 (1971), 270e275.

Shiina I, inventor; Tokyo University of Science, assignee. Dihydronaphthalene compound and use thereof. United States patent US 8,183,235. (2012), May 22.

B. Godin, E. Touitou, Ethosomes: new prospects in transdermal delivery, Crit. Rev. Ther. Drug Carrier Syst. 20 (1) (2003), 63–102.

S.S. Bodade, K.S. Shaikh, M.S. Kamble, P.D. Chaudhari, A study on ethosomes as mode for transdermal delivery of an antidiabetic drug, Drug Deliv. 20 (1) (2013), 40–46.

X. Zhu, F. Li, X. Peng, K. Zeng, Formulation and evaluation of lidocaine base ethosomes for transdermal delivery, Anesth. Analg. 117 (2013), 352–357.

Y.T. Zhang, L.N. Shen, Z.H. Wu, J.H. Zhao, N.P. Feng, Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy, Int. J. Pharm. 471 (2014), 449–452.

Mabry FS, inventor; Westinghouse Electric Corp, assignee. Terminus for concentric transmission lines. United States patent US 2,465,245. (1949), Mar 22.

Srinivasa, G.S., Yarena, K.J. Nanotechnologies for the Life Sciences: Dendrimers in Cancer Treatment and Diagnosis. Wiley, New York, (2007).

Dendrimers, Jain K, .In: Smart Nano-Engineered Polymers for Bioinspired Applications in Drug Delivery. Elsevier Ltd, pp. (2017), 169–220.

P. Kesharwani, L. Xie, S. Banerjee, G. Mao, S. Padhye, F.H. Sarkar, A.K. Iyer, Hyaluronic acid-conjugated polyamidoaminedendrimers for targeted delivery of 3, 4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells, Colloids Surf. B: Biointerfaces 136 (2015), 413–423.

Van S, inventor; Annam Biosciences, LLC, assignee. N-BOC-dendrimers and their conjugates. United States patent US 9,526,795. (2016), Dec 27.


Refbacks

  • There are currently no refbacks.